Kenneth W. Mahaffey
The University of Sydney
5 papers in the Anchorcite directory, published between 2009 and 2019, cited 37,254 times in total.
ORCID profileResearch topics
- Diabetes Treatment and Management · 2 papers
- Chronic Kidney Disease and Diabetes · 2 papers
- Acute Myocardial Infarction Research · 2 papers
- Acute Ischemic Stroke Management · 1 paper
- Atrial Fibrillation Management and Outcomes · 1 paper
- Venous Thromboembolism Diagnosis and Management · 1 paper
Frequent co-authors
- Richard Clinton Becker · 2 papers
- Keith A.A. Fox · 2 papers
- Bruce Charles Neal · 2 papers
- Vlado Perkovic · 2 papers
- Dick de Zeeuw · 2 papers
- Christopher Paul Cannon · 2 papers
- Stefan Karl James · 2 papers
- Hugo Albert Katus · 2 papers
Papers
- Rivaroxaban versus Warfarin in Nonvalvular Atrial FibrillationNew England Journal of Medicine · 2011 · 9,529 citations
BACKGROUND: The use of warfarin reduces the rate of ischemic stroke in patients with atrial fibrillation but requires frequent monitoring and dose adjustment. Rivaroxaban, an oral factor Xa inhibitor, may provide more consistent and predictable anticoagulation than warfarin. METHODS: In…
- Canagliflozin and Cardiovascular and Renal Events in Type 2 DiabetesNew England Journal of Medicine · 2017 · 8,032 citations
Background Canagliflozin is a sodium-glucose cotransporter 2 inhibitor that reduces glycemia as well as blood pressure, body weight, and albuminuria in people with diabetes. We report the effects of treatment with canagliflozin on cardiovascular, renal, and safety outcomes. Methods The…
- Ticagrelor versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine · 2009 · 7,173 citations
BACKGROUND: Ticagrelor is an oral, reversible, direct-acting inhibitor of the adenosine diphosphate receptor P2Y12 that has a more rapid onset and more pronounced platelet inhibition than clopidogrel. METHODS: In this multicenter, double-blind, randomized trial, we compared ticagrelor (180-mg loading dose,…
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyNew England Journal of Medicine · 2019 · 6,422 citations
BACKGROUND: Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium-glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal…
- Fourth universal definition of myocardial infarction (2018)European Heart Journal · 2018 · 6,098 citations
... ... ... ... In the late 19th century, post-mortem examinations demonstrated a possible relationship between thrombotic occlusion of a coronary artery and myocardial infarction (MI).1 However, it was not until the beginning of the 20th century that the first…
Metadata from OpenAlex (CC0).